OncLive.com (@onclive) 's Twitter Profile
OncLive.com

@onclive

Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.

ID: 43051682

linkhttp://www.onclive.com calendar_today28-05-2009 05:04:27

110,110K Tweet

46,46K Followers

1,1K Following

OncLive.com (@onclive) 's Twitter Profile Photo
OncLive.com
@onclive

2 days ago

Treatment with a novel, optimized, hinge dual CD19/CD20–directed CAR T-cell therapy was safe and elicited high response rates, particularly when administered after ASCT, in patients with relapsed/refractory B-cell #lymphoma. The EBMT #EBMT2025 hubs.ly/Q03h_GxD0

Treatment with a novel, optimized, hinge dual CD19/CD20–directed CAR T-cell therapy was safe and elicited high response rates, particularly when administered after ASCT, in patients with relapsed/refractory B-cell #lymphoma. <a href="/TheEBMT/">The EBMT</a> #EBMT2025 hubs.ly/Q03h_GxD0